Advertisement
Advertisement
NNNN
Anbio Biotechnology Class A Ordinary Shares
10.35
USDSponsored
+0.16
+1.57%
Aug 11, 15:58 UTC -4
Closed
Pre-Market
10.33
-0.02
-0.19%
NNNN Earnings Reports
Positive Surprise Ratio
No Data Available for NNNN
0%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q4 25 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Anbio Biotechnology Class A Ordinary Shares earnings per share and revenue
On Apr 27, 2026, NNNN reported earnings of -- USD per share (EPS) for Q4 25, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a --% difference.
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Bicara Therapeutics Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.84
Actual
-$0.82
Surprise
+3.18%
Autolus Therapeutics plc - ADR
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.22
Actual
-$0.15
Surprise
+31.82%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
$0.01
Actual
$0.05
Surprise
+400.00%
LENZ Therapeutics, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$1.09
Actual
-$1.02
Surprise
+6.95%
Codexis, Inc.
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.14
Actual
-$0.13
Surprise
+7.67%
Seer, Inc. Class A Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.31
Surprise
-12.56%
Liquidia Corporation Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
$0.75
Actual
$0.74
Surprise
-2.34%
Legend Biotech Corporation - ADR
Report Date
Aug 11, 2026 For Q2 26
Estimate
$0.07
Actual
$0.09
Surprise
+17.80%
Mineralys Therapeutics, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.54
Actual
-$2.85
Surprise
-422.26%
Imunon, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.94
Actual
-$0.54
Surprise
+42.83%
FAQ
What were Anbio Biotechnology Class A Ordinary Shares's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Anbio Biotechnology Class A Ordinary Shares reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Anbio Biotechnology Class A Ordinary Shares's Q4 2025 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Anbio Biotechnology Class A Ordinary Shares expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Anbio Biotechnology Class A Ordinary Shares's next earnings report?
Based on --
analysts, Anbio Biotechnology Class A Ordinary Shares is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement